02315.HK
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
HKSE · Healthcare · Biotechnology · CN
HKD 60.60
−5.53%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 2.9B | 1.4B | 980.5M | 716.9M | 533.9M |
| Cost of Revenue | 631.6M | 333.2M | 218.9M | 210.9M | 142.1M |
| Gross Profit | 2.2B | 1.0B | 761.5M | 506.0M | 391.8M |
| Operating Expenses | |||||
| R&D Expense | 863.9M | 438.1M | 323.9M | 474.4M | 699.2M |
| SG&A Expense | 773.0M | 400.5M | 311.4M | 349.1M | 313.7M |
| General & Admin Expense | 384.0M | 268.2M | 218.4M | 286.3M | 263.4M |
| Selling & Marketing Expense | 182.7M | 132.2M | 93.0M | 62.8M | 50.2M |
| Other Expenses | (85.9M) | (71.5M) | (38.1M) | (47.1M) | (15.1M) |
| Total Operating Expenses | 1.6B | 767.0M | 597.2M | 776.3M | 997.8M |
| Cost and Expenses | 2.2B | 1.1B | 816.1M | 987.2M | 1.1B |
| Operating Income (EBIT) | 698.5M | 278.6M | 164.4M | (270.3M) | (530.4M) |
| Non-Operating | |||||
| Interest Income | 12.0M | 4.3M | 5.9M | 10.2M | 2.2M |
| Interest Expense | 143.0M | 71.0M | 91.7M | 99.8M | 56.1M |
| Net Interest Income | (136.2M) | (66.7M) | (85.8M) | (89.7M) | (54.0M) |
| Other Non-Op Income/Expense | (171.6M) | (90.6M) | (121.4M) | (109.9M) | (70.9M) |
| Non-Operating Income (excl Interest) | 331.7M | 19.6M | 29.8M | 10.0M | 74.2M |
| EBT (Pre-Tax Income) | 526.9M | 188.0M | 42.9M | (380.2M) | (601.4M) |
| Income Tax Expense | 28.0M | 14.8M | 9.4M | 2.8M | 804.0K |
| Bottom Line | |||||
| Net Income | 495.2M | 173.2M | 33.5M | (383.0M) | (602.2M) |
| Earnings from Cont. Ops | 498.5M | 173.2M | 33.5M | (383.0M) | (602.2M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 495.2M | 173.2M | 33.5M | (383.0M) | (601.9M) |
| Per Share | |||||
| Basic EPS | HK$1.19 | HK$0.43 | HK$0.08 | (HK$0.96) | (HK$1.53) |
| Diluted EPS | HK$1.19 | HK$0.43 | HK$0.08 | (HK$0.96) | (HK$1.53) |
| Revenue Per Share | HK$6.49 | HK$3.45 | HK$2.46 | HK$1.80 | HK$1.36 |
| Shares | |||||
| Basic Shares Outstanding | 443.5M | 400.1M | 398.0M | 398.3M | 392.7M |
| Diluted Shares Outstanding | 443.5M | 400.1M | 398.0M | 398.3M | 392.7M |
| Profitability Metrics | |||||
| EBITDA | 967.5M | 419.5M | 303.8M | (97.9M) | (465.9M) |
| D&A | 295.6M | 160.5M | 169.2M | 182.4M | 138.7M |
| EBIT | 671.9M | 259.0M | 134.6M | (280.3M) | (604.6M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026